By Facsimile

Date of Deposit: May 31, 2007

Attorney Docket No. 34407-501 CIP1DIV

RECORDATION FORM COVER SHEET PATENTS ONLY					
FORM PTO-1595 (Rev. 6-93) OMB No. 0651-0011 (exp. 4/94)	U,S, DEPARTMENT OF COMMERCE Patent and Trademark Office				
Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): University of Bristol Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No 3. Nature of conveyance: ☒ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other ☐ Other	2. Name and address of receiving party(ies) Name: Trident Pharmaceuticals, Inc. Internal Address: 75 State Street Boston, MA 02109 Street Address: Same as above				
Additional name(s) & address(es) attached? []Yes [X] No Execution Date: March 16, 2006 4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is A. Patent Application No(s): B. Patent No(s):					
11/240,134 Additional numbers attached? ☐ Yes ☒ No					
5. Name and address of party to whom correspondence Concerning document should be mailed: Name: Ivor R. Elrifi Address: MINTZ, LEVIN, COHN, FERRIS GLOVSKY and POPEO, P.C. One Financial Center Boston, MA 02111	 6. Total number of applications and patents involved: [1] 7. Total fee (37 CFR 3.41) \$40.00 ☐ Enclosed ☑ The Commissioner is authorized to charge Deposit Account No: 50-0311, Reference No. 34407-501 CIP1DIV. 				
DO NOT USE THIS SPACE					
9. Statement and signature To the best of my knowledge and belief, the foregoing information is true and of Sean M. Coughlin, Reg. No. 48,593 Name of Person Signing Signature	May 31, 2006				
Total number of pages including cover sheet, attachments, and document: [5]					

Mail documents to be recorded with required cover sheet information to:

MAIL STOP Assignment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

4057994v.1

ישוביבט סט ואו ב-

durphy

0117 900 8242

р. Э

Express Mall Label No.; Date of Deposit:

Attorney Docket No.: 34407-501, -502, -503

ASSIGNMENT

The University of Bristol, an entity having offices at Senate House, Tyndail Avenue, Clifton, Bristol BS8 1TH, Great Britain ("ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to Trident Pharmaceuticals, Inc., a Delaware corporation having principal offices at 75 State Street, Boston, MA 02109, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in its name as the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof and any substitute applications therefor, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

ASSIGNOR hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

ASSIGNOR agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

ASSIGNOR further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do that necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR hereby covenants that it has obtained full right to convey the entire interests listed in Schedule A by virtue of prior assignments, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

Apr 06 09:23

0117 900 8242

16-MAR-2006 10:53 From:

ASSIGNOR flother covenants that ASSIGNEE will, upon its request, he provided promptly with all pertinent lasts and documents relating to said invention and said Letters Patent and lags! equivalents as may be known and accessible to ASSKINOR and will result; as to the same in any interference. Highlin or proceeding related therein and will promptly execute and deliver to ASSKINHI or its legal representatives any and all papers, instruments or stifidevits required to early for obtain, maintain, issue and enforce said application, said invention and said Letters Paters and said equivalents time of which may be necessary or desirable to easily out the purposes

For The University of Bristol

Data:

Mynaters of

HILLIAM MAN

Title: Digarry Frances Directors. The University of Bristol

IN WITNESS WHEREOF, I hereunto act hand

IN WITNESS WHEREOF, I hereunto not hand

Signature of witness

JENNER J. C.CCC

Name of witness

Date of Horeing

Signature of withest

NEL AUGUA

Name of witness

this 16 day of 1 Date of signing

For Trident Pharmaceuticals Inc

Signature of: RUBIN BROWN

Title: DIRECTOR

Trident Pharmaceuticals Inc.

Signature Page to Assignment

p.5

20 Hpr 06 09:23

Murphy

0117 900 8242

Attorney Docket No.: 34407-501, -502, -503

SCHEDULE A

PCT	Title	Stage/Territory	Application and/or Patent	Reel/Frame
Australia 724516 Canada 2225788 China 96196258.5 Czech Republic Europe EP 0841939 €. Hong Kong HK 1006496 ∳— Hungary 224248 Japan 9-504927 K. Orea (South) 0452000 Mexico 9800241 Norway 319747 New Zealand 187266 Russia 98101907 Singapore 50173 USA 08/999458; US 6,287,563 014066/0524; 014484/0401 US-CIP 09/867,914 014070/0650 US-CIP Div 1 10/240,134 see 014070/0650 PCT PCT/GB99/00070 Australia 762478 Canada 2,317,443 Europe 99900567.1 ♥ Japan 2000-527265 New Zealand 526218 USA 09/600,060 014070/0450 Vaccine PCT PCT/GB99/01461 Australia 2003261492 Canada 2331832 China 99908403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 999922284.7 ♥ . Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM	<u> </u>		No.	No(s).
Canada 2225788		PCT		
China 96196258.5 Czech Republic PV 12-98 Burope BP 0841939 ★		Australia	724516	
Czech Republic PV 12-98		Canada		
Europe	·	China	96196258.5	
Europe	ļ ·	Czech Republic	PV 12-98	
Hungary 224248 Japan 9-504927 Korea (South) 0452000 Mexico 9800241 Mexico 9800076 Mexico 98009076 Mexico 98099458; US 6,287,563 014066/0524; 014484/0401 US-CIP 09/867,914 014070/0650 US-CIP 09/867,914 014070/0650 Mexico 97000070 Mexico 970000070 Mexico 9	1		EP 0841939 🗲	
Hungary 224248 Japan 9-504927 Korea (South) 0452000 Mexico 9800241 Mexico 9800076 Mexico 98009076 Mexico 98099458; US 6,287,563 014066/0524; 014484/0401 US-CIP 09/867,914 014070/0650 US-CIP 09/867,914 014070/0650 Mexico 97000070 Mexico 970000070 Mexico 9	1	Hong Kong	HK 1006496 +	
Therapeutic Agents and autoimmune diseases			224248	
Korea (South) 0452000 0452000		Japan	9-504927	
Mexico 9800241		Korea (South)	0452000	
Norway 319/4/ New Zealand 187266 Poland 187266 Russia 98101907 Singapore 50173 USA 08/999458; US 6,287,563 014066/0524; 014484/0401 US-CIP 09/867,914 014070/0650 US-CIP Div 1 10/240,134 see O14070/0650 PCT PCT/GB99/00070 Australia 762478 treating allergic or Europe 99900567.1			9800241	
New Zealand 187266		Norway	319747	
Russia 98101907	diseases	New Zealand		
Russia 98101907		Poland	187266	
Singapore S0173 USA 08/999458; US 6,287,563 014066/0524; 014484/0401 US-CIP 09/867,914 014070/0650 US-CIP - Div 1 10/240,134 see 014070/0650 PCT PCT/GB99/00070 Australia 762478 Treating allergic Canada 2,317,443 Canada 2,317,443 Canada 2000-527265 Canada C		Russia	98101907	
USA 08/999458; US 6,287,563 014066/0524; 014484/0401 US-CIP		Singapore	50173	
US-CIP - Div 1 10/240,134 see 014070/0650			08/999458; US 6,287,563	
US-CIP - Div 1 10/240,134 see 014070/0650		US-CIP	09/867,914	014070/0650
Agent for Australia 762478 treating allergic or Burope 99900567.1 ★ hypersensitivity Japan 2000-527265 condition New Zealand 526218 USA 09/600,060 014070/0450 Vaccine PCT PCT/GB99/01461 Australia 2003261492 Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 ★ Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM			10/240,134	w
Agent for treating allergic or hypersensitivity condition Australia 762478 New Zealand USA 2,317,443 Vaccine PCT PCT/GB99/01461 Australia 2003261492 Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Europe 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2900,00589/MUM		PCT	PCT/GB99/00070	
treating allergic or Europe 99900567.1 % hypersensitivity condition Description	Agent for			
or hypersensitivity condition				·
hypersensitivity condition New Zealand 526218	1 -			
New Zealand S26218 USA 09/600,060 014070/0450	hypersensitivity			
USA 09/600,060 014070/0450 Vaccine PCT PCT/GB99/01461 Australia 2003261492 Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				
Vaccine PCT PCT/GB99/01461 Australia 2003261492 Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				014070/0450
Australia 2003261492 Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM	Vaccine	PCT		
Canada 2331832 China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 ♣ Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM	,			
China 99808403.4 Czech Republic PV 2000-4147 Eurasia 004794 Burope 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				
Czech Republic PV 2000-4147 Eurasia 004794 Europe 99922284.7 ★6. Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				
Eurasia 004794 Europe 99922284.7 Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM	1			
Europe 99922284.7 \$\frac{1}{2}\$. Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				· · · · · · · · · · · · · · · · · · ·
Hungary P 0104842 Israel 139467 India IN/PCT/2000,00589/MUM				
Israel 139467 India IN/PCT/2000,00589/MUM				
India IN/PCT/2000,00589/MUM				
		India	00353/MUMNP/2004 - B	-
divisional application from	1		divisional application from	

20 Apr 06 09:24

durphy

0117 900 8242

p.6

Title	Stage/Territory	Application and/or Patent No.	Recl/Frame No(s).
		IN/PCT/2000,00589/MUM	
•	Japan	2000-547996	
	Korea	2000-7012486	
	Mexico	010934	
	New Zealand	507911	
	Norway	20005599	
	Poland	P344519	
	Singapore	77072	
	South Africa	2000/6160	
	Ukraine	2000127088/M	
	USA	09/674,935	014273/0231

TRA 2128287v.1

2

By Via Facsimile

Attorney Docket No. 34407-501 CIP1DIV

Date of Deposit: May 31, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Williams et al.

SERIAL NO.:

11/240,134

EXAMINER

Michael L. Borin

FILING DATE:

September 30, 2005

ART UNIT

1631

For:

THERAPEUTIC AGENTS

Fax Cover Sheet

DATE:

May 31, 2007

FROM:

Sean M. Coughlin

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC

Direct Dial

202-585-3577

smcoughlin@mintz.com

To:

NAME	Business #	FAX#
United States Patent and Trademark	·	571-273-0140
Office		
Attention: Mail Stop Assignment		

Pages: 6

MESSAGE:

Request for Recordation of Assignment

Please call us at 202-585-3577, if you experience any problems.

STATEMENT OF CONFIDENTIALITY

THE INFORMATION CONTAINED IN THIS FAX IS INTENDED FOR THE EXCLUSIVE USE OF THE ADDRESSEE AND MAY CONTAIN CONFIDENTIAL OR PRIVILEGED INFORMATION. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY FORM OR DISSEMINATION OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF THIS FAX WAS SENT IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY PHONE.

RECORDED: 05/31/2007

REEL: 019372 FRAME: 0133